Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.67 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13133179 | 1.00 | HCAR2 (0.67) | HCAR2NFE2L2KEAP1CA12CA1 | |
| SCHEMBL13133177 | 1.00 | HCAR2 (0.67) | HCAR2NFE2L2KEAP1CA12CA1 | |
| Methoxymethane SCHEMBL22042961 | 0.90 | HCAR2 (0.73) | HCAR2NFE2L2KEAP1CA12CA1 | |
| SCHEMBL177748 | 0.89 | HCAR2 (0.80) | HCAR2NFE2L2KEAP1CA12CA1 | |
| SCHEMBL178194 | 0.89 | HCAR2 (0.80) | HCAR2NFE2L2KEAP1CA12CA1 | |
| SCHEMBL177747 | 0.89 | HCAR2 (0.80) | HCAR2NFE2L2KEAP1CA12CA1 | |
| SCHEMBL18421667 | 0.85 | HCAR2 (0.65) | HCAR2NFE2L2KEAP1CA12CA1 | |
| SCHEMBL2609734 | 0.85 | HCAR2 (0.65) | HCAR2NFE2L2KEAP1CA12CA1 | |
| SCHEMBL18213889 | 0.85 | HCAR2 (0.52) | HCAR2NFE2L2KEAP1CA12CA1 | |
| SCHEMBL2609729 | 0.83 | HCAR2 (0.50) | HCAR2NFE2L2KEAP1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | ARBOR PHARMACEUTICALS, LLC | 2021-07-29 | — | — | US | disclosed |
| US-10945984-B2 | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| EP-1533322-B1 | SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND CATALYST | TOHO TITANIUM CO LTD (JP) | 2019-05-01 | — | — | EP | disclosed |
| US-9562119-B2 | Ethylene polymerization catalysts | W. R. GRACE & CO.-CONN. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-3027767-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XenoPort, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20150307914-A9 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | ARBOR PHARMACEUTICALS, LLC | 2015-10-29 | — | — | US | disclosed |
| WO-2015017762-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XENOPORT, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20150038499-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XENOPORT INC (US) | 2015-02-05 | — | — | US | disclosed |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140057917-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2576633-A2 | ETHYLENE POLYMERIZATION CATALYSTS | BASF Corporation (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011149656-A2 | ETHYLENE POLYMERIZATION CATALYSTS | BASF CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110294970-A1 | ETHYLENE POLYMERIZATION CATALYSTS | BASF CATALYSTS, LLC (US) | 2011-12-01 | — | — | US | disclosed |
| US-20050227856-A1 | Solid catalyst component for olefin polymerization and catalyst | TOHO CATALYST CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| EP-1533322-A1 | SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND CATALYST | Toho Catalyst Co., Ltd. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038499-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | HCAR2 3998/4885NFE2L2 1099/4885KEAP1 1101/4885 |
| US-20140057917-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | HCAR2 1463/4885NFE2L2 2050/4885KEAP1 2871/4885 |
| US-10945984-B2 | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects | FH, FAH, ALDOA | HCAR2 1463/4885NFE2L2 2050/4885KEAP1 2871/4885 |
| US-20110294970-A1 | ETHYLENE POLYMERIZATION CATALYSTS | ESR1, MSMO1, MCM5 | HCAR2 3524/4885NFE2L2 535/4885KEAP1 1010/4885 |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | HCAR2 1463/4885NFE2L2 2050/4885KEAP1 2871/4885 |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | HCAR2 3998/4885NFE2L2 1099/4885KEAP1 1101/4885 |
| US-20150307914-A9 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | HCAR2 3998/4885NFE2L2 1099/4885KEAP1 1101/4885 |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | HCAR2 1463/4885NFE2L2 2050/4885KEAP1 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.